GlassScriptPhysician profile
Ramesh B Cherukuri
NPI 1952668543
$15,627.55
in general payments reported to CMS, 2019-2025
56 companies · $23.76 in 2025
The $23.76 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,018 · 2020: $1,324 · 2021: $2,342 · 2022: $3,318 · 2023: $3,207 · 2024: $3,396 · 2025: $23.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,607 · Education: $19.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,607.28 |
| Education | $19.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,363.14 | 2021-2024 | Qulipta, Duopa, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $1,043.29 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ucb, INC. | $920.09 | 2021-2024 | Briviact, Nayzilam, Zilbrysq |
| Genzyme Corporation | $900.13 | 2019-2024 | |
| Sk Life Science, INC. | $728.71 | 2020-2024 | |
| Lilly USA, LLC | $720.52 | 2019-2024 | Emgality, Amyvid, Reyvow |
| Amneal Pharmaceuticals LLC | $674.01 | 2019-2024 | Rytary, Lyvispah, Crexont |
| Novartis Pharmaceuticals Corporation | $627.78 | 2019-2024 | |
| Pfizer INC. | $580.65 | 2019-2024 | |
| Amgen INC. | $533.80 | 2019-2022 | |
| Genentech USA, INC. | $434.47 | 2019-2023 | Enspryng, Ocrevus |
| Argenx US, INC. | $410.83 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Biogen, INC. | $409.61 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Supernus Pharmaceuticals, INC. | $394.27 | 2019-2023 | Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $364.86 | 2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Cherukuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.